397 related articles for article (PubMed ID: 16377540)
21. Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Asatiani E; Kessler CM;
Haemophilia; 2007 Nov; 13(6):685-96. PubMed ID: 17973844
[TBL] [Abstract][Full Text] [Related]
22. [A new therapy of hemophilia with ranitidine].
Hu LM; Ye LL; Xu B
Zhonghua Nei Ke Za Zhi; 1990 Feb; 29(2):85-7, 125. PubMed ID: 2120016
[TBL] [Abstract][Full Text] [Related]
23. The spectrum of inherited bleeding disorders in pediatrics.
El-Bostany EA; Omer N; Salama EE; El-Ghoroury EA; Al-Jaouni SK
Blood Coagul Fibrinolysis; 2008 Dec; 19(8):771-5. PubMed ID: 19002043
[TBL] [Abstract][Full Text] [Related]
24. Plasma derivatives: new products and new approaches.
Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
[TBL] [Abstract][Full Text] [Related]
25. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
26. The future of plasma-derived clotting factor concentrates.
Hoots WK
Haemophilia; 2001 Jan; 7 Suppl 1():4-9. PubMed ID: 11240612
[TBL] [Abstract][Full Text] [Related]
27. Safety and supply of haemophilia products: worldwide perspectives.
Farrugia A
Haemophilia; 2004 Jul; 10(4):327-33. PubMed ID: 15230945
[TBL] [Abstract][Full Text] [Related]
28. Immunologic studies in asymptomatic hemophiliac patients.
Frydecka I; Kowalewska B; Lesiecki A; Kuliczkowski K; Palakowska A; Polkowski A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):708-15. PubMed ID: 2435638
[TBL] [Abstract][Full Text] [Related]
29. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.
Franchini M; Makris M; Santagostino E; Coppola A; Mannucci PM
Haemophilia; 2012 May; 18(3):e164-72. PubMed ID: 22250981
[TBL] [Abstract][Full Text] [Related]
30. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
31. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
Berntorp E; Astermark J; Baghaei F; Bergqvist D; Holmström M; Ljungberg B; Norlund A; Palmblad J; Petrini P; Stigendal L; Säwe J
Haemophilia; 2012 Mar; 18(2):158-65. PubMed ID: 22151198
[TBL] [Abstract][Full Text] [Related]
32. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Federici AB
Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
[TBL] [Abstract][Full Text] [Related]
33. Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
Schramm W
Haemophilia; 2008 Nov; 14 Suppl 5():3-10. PubMed ID: 18786006
[TBL] [Abstract][Full Text] [Related]
34. The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.
Federici AB; Santagostino E; Rumi MG; Russo A; Mancuso ME; Soffredini R; Mannucci PM; Colombo M
Haematologica; 2006 Apr; 91(4):503-8. PubMed ID: 16585016
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
37. Product delivery in the developing world: options, opportunities and threats.
Farrugia A
Haemophilia; 2004 Oct; 10 Suppl 4():77-82. PubMed ID: 15479376
[TBL] [Abstract][Full Text] [Related]
38. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
Jacquemin M
Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
[TBL] [Abstract][Full Text] [Related]
39. [Clotting factor concentrates].
Barthels M; Oldenburg J
Hamostaseologie; 2008 Dec; 28(5):387-99. PubMed ID: 19132169
[TBL] [Abstract][Full Text] [Related]
40. Prevention of hepatitis C virus infection in children with haemophilia A and B and von Willebrand's disease.
Kreuz W; Auerswald G; Brückmann C; Zieger B; Linde R; Funk M; Auberger K; Sutor AH; Rasshofer R; Roggendorf M
Thromb Haemost; 1992 Jan; 67(1):184. PubMed ID: 1615476
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
